A multicentre, retrospective, real-world study assessing the hepatitis B virus infection prophylaxis in treatment with Ocrelizumab, Rituximab and Cladribine in patients with Multiple Sclerosis
Latest Information Update: 08 Jun 2022
At a glance
- Drugs Cladribine (Primary) ; Ocrelizumab (Primary) ; Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics
- 01 Jun 2022 Results published in the Journal of Neurology
- 20 Dec 2021 New trial record